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Abstract
Introduction: Lupus nephritis (LN) is a severe and frequent manifestation of systemic lupus erythematosus (SLE). Its
pathogenesis has not been fully elucidated but immune complexes are considered to contribute to the inflammatory
pathology in LN. High Mobility Group Box 1 (HMGB1) is a nuclear non-histone protein which is secreted from different
types of cells during activation and/or cell death and may act as a pro-inflammatory mediator, alone or as part of DNA-
containing immune complexes in SLE. Urinary excretion of HMGB1 might reflect renal inflammatory injury. To assess
whether urinary HMGB1 reflects renal inflammation we determined serum levels of HMGB1 simultaneously with its
urinary levels in SLE patients with and without LN in comparison to healthy controls (HC). We also analyzed urinary
HMGB1 levels in relation with clinical and serological disease activity.
Methods: The study population consisted of 69 SLE patients and 17 HC. Twenty-one patients had biopsy proven active
LN, 15 patients had a history of LN without current activity, and 33 patients had non-renal SLE. Serum and urine levels of
HMGB1 were both measured by western blotting. Clinical and serological parameters were assessed according to routine
procedures. In 17 patients with active LN a parallel analysis was performed on the expression of HMGB1 in renal biopsies.
Results: Serum and urinary levels of HMGB1 were significantly increased in patients with active LN compared to
patients without active LN and HC. Similarly, renal tissue of active LN patients showed strong expression of HMGB1
at cytoplasmic and extracellular sites suggesting active release of HMGB1. Serum and urinary levels in patients
without active LN were also significantly higher compared to HC. Urinary HMGB1 levels correlated with SLEDAI,
and showed a negative correlation with complement C3 and C4.
Conclusion: Levels of HMGB1 in urine of SLE patients, in particular in those with active LN, are increased and correlate
with SLEDAI scores. Renal tissue of LN patients shows increased release of nuclear HMGB1 compared to control renal
tissue. HMGB1, although at lower levels, is, however, also present in the urine of patients without active LN. These data
suggest that urinary HMGB1 might reflect both local renal inflammation as well as systemic inflammation.
Introduction
Systemic lupus erythematosus (SLE) is a prototypic sys-
temic autoimmune disease characterized by a wide array
of autoantibodies, mainly against nuclear components.
Autoantibody production is associated with various clini-
cal manifestations and among these manifestations, renal
involvement, that is, lupus nephritis (LN), is the most
serious clinical problem predicting morbidity and mortal-
ity [1,2]. The mechanisms underlying the pathogenesis of
LN are not fully elucidated. However, LN has often been
considered an inflammatory disease resulting from
deposition of preformed immune complexes or binding
of autoantibodies to antigens localized to glomeruli, so-
called in situ complex formation [3-5]. Among the many
antibodies potentially participating in the formation of
immune complexes, antibodies against DNA are the hall-
mark of SLE. Recently, it has been shown that these
DNA-containing immune complexes constitute among
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others, high mobility group box 1 (HMGB1), which has
been suggested to be involved in binding of these
immune complexes to renal tissue and initiate renal
injury [6].
HMGB1 is a nuclear DNA-binding protein that resides
inside the nucleus and can be released to the extracellular
space under specific conditions [7,8]. Whereas HMGB1 is
actively released from lipopolysaccharide (LPS), TNF-, and
IL-1 activated monocytes and macrophages, its release
also occurs passively during the late phase of apoptosis as
well as during necrosis [7,9,10]. Extracellularly, HMGB1
acts as an alarmin involved in inflammatory reactions
through binding to its functional receptors, that is the
receptor of advanced glycation end products (RAGE) and
toll-like receptors (TLR)-2, -4, and -9 [11-14].
There is accumulating evidence that HMGB1 contributes
to the pathogenesis of inflammatory and autoimmune dis-
eases, especially SLE [15-17]. This is related to the fact that
apoptotic cells accumulate in SLE and are the main source
of autoantigens, including HMGB1 [7,18]. We and others
showed that serum levels of HMGB1 are elevated in SLE
patients and correlate with SLE disease activity score and,
inversely, with levels of the complement components C3
and C4. Moreover, we could demonstrate that serum levels
of HMGB1, in particular, were increased in SLE patients
with active renal disease and correlated with proteinuria
[15]. The origin of the increased serum levels of HMGB1 is
not known, and HMGB1 could possibly result from release
from damaged and/or inflamed renal tissue. As such,
HMGB1 could appear in the urine during (active) LN. In
this study, we hypothesize that urinary excretion of
HMGB1 reflects renal inflammatory injury in SLE. We
investigated this by measuring HMGB1 levels in the urine
of SLE patients and correlating this to clinical and bio-
chemical measures of renal and systemic disease activity.
Materials and methods
Patients
Sixty-nine patients (nine male, sixty female), median age
41 (range 16 to 81) years, who fulfilled at least four of the
American College of Rheumatology (ACR) revised criteria
for the diagnosis of SLE, and seventeen healthy controls
(HC) (two male, fifteen female), median age 26 (range 20
to 59) years were enrolled in the study. The study was
approved by the Medical Ethical Committee of the Univer-
sity Medical Center Groningen, University of Groningen,
the Netherlands, and all patients and HC gave informed
consent. Clinical data were obtained from all patients and
the study was conducted according to the ethical guide-
lines of our institution in accord with the Declaration of
Helsinki. Among the patients, 21 had biopsy-proven active
LN, 15 had a history of LN without current activity, and
33 had non-renal SLE (Table 1). Disease activity at the
time of blood sampling was assessed by the SLE disease
activity index (SLEDAI). Currently active LN (n = 21) was
defined as proliferative glomerulonephritis (class III or IV)
in a parallel-obtained renal biopsy (n = 17) or as the pre-
sence of an active urinary sediment representing glomeru-
lar injury in a patient with biopsy-proven LN before.
Blood and urine was obtained when patients were
admitted, at a maximum of 3 days before a renal biopsy
was taken. Further characteristics of the patients are sum-
marized in Table 1.
Materials
Serum and urine samples were collected from patients
and HC. Patients’ urine samples that were nitrite-posi-
tive urine samples on a dip stick test or demonstrated
evidence of bacterial contamination in the sediment
were excluded. Levels of anti-dsDNA, C-reactive protein
(CRP), creatinine (Cr), and complement factors (C3, C4)
in sera, and 24 hr proteinuria and urine Cr levels were
determined by routine techniques.
Paraffin-embedded sections of renal biopsy specimens
obtained from 17 patients with active LN were included
in the present study. Renal tissues from three unaffected
parts of the kidneys of patients with renal cell carci-
noma were used as controls.
Western blot for serum and urine HMGB1
Serum and urine samples from SLE patients and HC
were collected and analyzed for HMGB1 by Western
Blotting as described previously. Western blot was cho-
sen because commercially available ELISA kits are not
suitable for SLE sera, due to interference of autoantibo-
dies (15). Also these kits are not recommended for urine
samples. Reproducibility was calculated over the positive
control in eight blots performed on different days and
coefficient of variation was 22.1%.
Urine samples were concentrated between 30 and 300
times using Vivaspin 15R (Sartorius Stedim Biotech, Got-
tingen, Germany). Serum and urine samples from SLE
patients and HC were diluted in SDS buffer (0.063 M
Tris.HCl pH 6.8, 2% SDS, 10% glycerol, 0.015% Brome-
Phenol Blue, and 5% ß-mercaptoethanol) and heated at
98ºC for five minutes. The volume of urine loaded to the
gel was corrected for the concentration factor. Next, pro-
teins were resolved on 12.5% SDS-PAGE gel (Criterion
gel BioRad, Veenendaal, The Netherlands) and trans-
ferred to polyvinylidene fluoride membrane (Millipore,
Amsterdam, The Netherlands) followed by incubation
with anti-HMGB1 mouse monoclonal antibody (1:250;
R&D Systems, Abingdon, UK). Detection was done with
polyclonal goat anti-mouse IgG labelled with IRDye800
(1: 5000; LI-COR Biotechnology, Westburg, Leusden, the
Netherlands). Blots were scanned with Odyssey infrared
Imaging System (LI-COR Biotechnology) and then ana-
lyzed with the Odyssey software (version 2.1). A standard
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sample was obtained from lyzed human keratinocyte
HaCaT cells and included in each blot as an internal con-
trol. In each blot, levels of HMGB1 were expressed as
values of fluorescence intensity and were normalized
against the standard sample. Urinary HMGB1 was
expressed as HMGB1/Cr ratio (intensity units/mmol/l)
to correct for differences in dilution.
Analysis of renal biopsies
Biopsies concomitantly taken with serum and urine sam-
ples were processed. All biopsies were reviewed and classi-
fied by an experienced nephropathologist (MCvD)
according to the revised criteria for LN [19]. The activity
index (AI) and chronicity index (CI) were calculated for
each specimen with maximum scores of 24 for the AI and
12 for the CI [19]. Histological data are shown in Table 2.
Immunohistochemical staining of renal biopsies
Kidney sections (4 µm) were used for all staining experi-
ments. Sections were deparaffinised. Next, antigen retrie-
val and endogenous peroxidase blocking was performed.
Slides were incubated with rabbit anti-HMGB1 antibody
(Abcam, Cambridge, UK), goat anti-RAGE antibody (AbD
Serotec, Dusseldorf, Germany), rabbit anti-TLR2 antibody
(Abcam), and rabbit anti-TLR-4 antibody (Abcam). Subse-
quently, slides were incubated with HRP-labelled second-
ary antibodies (DakoCytomation, Glostrup, Denmark).
Next, slides were incubated in diaminobenzidine solution
and counterstained with hematoxylin. Using ImageScope
software (Aperio Technologies, Vista, CA, USA) morpho-
metry was performed on entire renal sections stained with
antibodies against RAGE, TLR2 and TLR4.
Analysis of immunohistochemical staining
Evaluation of HMGB1 staining
The stained slides were coded and analyzed indepen-
dently by two observers (DA and JW) in a blinded fash-
ion. Cellular distribution of HMGB1 was determined in
the kidney by counting one hundred nuclei in three
brightfield pictures and scoring both HMGB1-positive
(brown) and HMGB1-negative (blue) nuclei. Results are
expressed as the percentage of negative cells.
Evaluation of TLR2, TLR4 and RAGE staining
Expression of TLR 2, TLR4 and RAGE was analyzed on
entire renal tissue sections of active LN patients and con-
trols stained with antibodies against TLR2, TLR4 and
RAGE.
Glass slides were digitally scanned with 20× objective
using Aperio ScanScope (Aperio Technologies). The
images were quantitatively analyzed and enhanced using
the computer software system ImageScope (Aperio Tech-
nologies) for histological examination. The positive pixel
count algorithm was used to quantify the amount of a spe-
cific stain present in a scanned image. Colour (range of
Table 1 Demographic, clinical and laboratory data of systemic lupus erythematosus (SLE) patients at the time of the
study
Active LN No active LN
History of LN No history of LN
Total number 21 15 33
Male/female, number 4/17 3/12 2/31
Age, years, median (range) 38 (16 to 53) 46 (18 to 61) 48 (20 to 81)
SLEDAI, mean ± SD 13.7 ± 3.7 ***,+++ 2.7 ± 1.7 2.8 ± 2.7
Anti-dsDNA antibody, IU/ml, median (range) 140 (3 to 1,000) **, + 19 (3 to 432) 20.5 (3 to 1000)
C3, g/l, median (range) 0.55 (0.27 to 1.13)***,++ 0.93 (0.43 to 1.48) 0.97 (0.31 to 11.4)
C4 (g/l), median (range) 0.08 (0.03- 0.3)*,+ 0.16 (0.06 to 0.3) 0.12 (0.02 to 1.04)
CRP, mg/I, median (range) 5 (5 to 121) 5 ( 5 to 21) 5 (5 to 33)
eGFR, ml/min 72 (24 to 142) 81 (45 to 145) 89 (31 to 140)
Serum creatinine, µmol/l, median (range) 75 (46 to 406) 71 (51 to 126) 62 (47 to 141)
24-hr proteinuria, g/24hr 1.5 (0.3 to 8.4)***,+++ 0.3 (0.2 to 2.5) # # # 0.0 (0.0 to 0.1)
Urine creatinine, mmol/l, median (range) 7.6 (0.6 to 21.3) 4.3 (1.6 to 15.7) 6.2 (0.7 to 14.9)
With/without treatment, number 12/9 13/2 21/12
Patients using prednisone, number (%), dose, mg/day, median (range) 10 (47.6%)
7.5 (2.5 to 60)
10 (66.6%)
10 (5 to 60)
8 (24.2%)
5 (1.25 to 10)
Patients taking hydroxychloroquine, number (%), dose, mg/day,
median (range)
8 (38%)




400 (200 to 600)
Patients using azathioprine, number (%), dose, mg/day, median (range) 3 (14.3%)




125 (75 to 150)
+Indicates difference between active lupus nephritis (LN) patients and patients with no active LN but with history of LN (+P ≤ 0.05, ++P ≤ 0.005, +++P ≤ 0.0005).
*Indicates difference between active and inactive SLE patients (*P = 0.05,**P ≤ 0.005, ***P ≤ 0.0005). #Indicates difference between patients without active LN but
with history of LN and inactive SLE patients with no history of LN (#P = 0.05, ##P ≤ 0.005, ###P ≤ 0.0005). Anti-dsDNA: anti-double stranded DNA; C3: Complement
3; C4 Complement 4; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; SLEDAI: systemic lupus erythematosus disease activity index.
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hues and saturation) and intensity were specified. For pix-
els that satisfied the colour specification, the algorithm
counted the number and intensity sum in each intensity
range. Positive colour class was divided into three intensity
ranges producing four categories of staining, namely
strong, medium, weakly positive, and negative staining.
Each pixel that stained was put into one of the four cate-
gories and total pixel counts were reported, along with
intensity, for each category. The percentage of positivity
was calculated by using the average of positive intensities
divided by the total numbers of positively and negatively
stained pixels.
Statistical analysis
Data are presented as median (range) unless stated
otherwise. Statistical analysis was performed by using
the statistical package Graph Pad Prism, version 3.02
(Graph Pad software Inc., San Diego, CA, USA). A stu-
dent Mann-Whitney test was performed for comparison
of different groups as appropriate. Spearman rank corre-
lation was used to assess correlations. A P- value < 0.05
was considered significant.
Results
Serum and urine HMGB1 levels
Serum HMGB1 levels in active LN patients were signifi-
cantly increased (intensity 57, range 11 to 350) compared
to HC (intensity 6, 1 to 38) and also compared to patients
without active LN (intensity 16, 2 to 92) (Figure 1A).
Patients without active LN, but with a history of renal
involvement had relatively higher levels of serum
HMGB1 (intensity 20, 2 to 80) compared to those with-
out renal involvement (intensity 13, 2 to 92), but this dif-
ference was not statistically significant.
Representative blots of urine measurements of HMGB1
are shown in Figure 1D. In lanes 3, 5, 7, 9, 11, 13 and 15,
patients’ samples were run (even lanes were left empty),
while in lanes 2 and 18 the positive control is shown. In
each blot a urine sample of a HC was run in lane 17,
whereas a molecular weight marker was run in lane 1.
Urinary HMGB1 levels were significantly increased in
patients with active LN (intensity 54, 4 to 300) compared
to HC (intensity 0, 0 to 4) and to patients with no active
LN (intensity 4, 0 to 300) (Figure 1B). In patients with no
active LN but having a history of LN, levels of urinary
HMGB1 were increased (intensity 20, 0 to 300), but not
significantly compared to patients without a history of LN
(1, 0 to 87) (Figure 1B). To correct for dilution, urinary
levels were expressed as HMGB1/Cr ratios. In Figure 1C
these ratios are shown in the patient groups, and also here
a significant difference was seen between patients with
active LN and patients without active LN.
Correlation of urine HMGB1 levels with clinical and
serological findings
Since urine levels of HMGB1 were increased in SLE
patients, particularly in patients with active LN, we
investigated whether urine levels of HMGB1 were
Table 2 Histological data of renal biopsies from seventeen systemic lupus erythematosus (SLE) patients with active
renal disease and three controls
Number Sex ISN class Activity index(AI) Chronicity index(CI) HMGB1-negative nuclei in renal tissues, %
1 F IV 10 3 35.0
2 F III 3 7 40.0
3 F III 2 0 25.0
4 F IV 8 0 20.4
5 F III 3 0 28.1
6 F III 1 4 29.4
7 F IV 5 0 37.2
8 F IV 3 2 24
9 F IV 5 3 38
10 F III 4 3 26
11 F IV 3 0 42
12 F III 2 0 0.7
13 F III 7 2 31.1
14 M III 3 0 12
15 M na 1 0 19.1
16 F IV 6 2 26.3
17 F IV 8 3 26.3
18 Control F - - - 0
19 Control F - - - 0
20 Control F - - - 0
M: male; F: female; ISN: International Society of Nephrology; HMGB1: high mobility group box 1; na: not assessed.
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related to clinical and serological parameters of disease
activity, and might thus be used as an additional marker
for assessment of disease activity, in particular renal
activity. We observed a positive correlation between
urine HMGB1/Cr ratios and SLEDAI (r = 0.54, P <
0.0001) (Figure 2A). Also, a significant negative correla-
tion was observed between levels of C3 and urinary
HMGB1/Cr ratios (r = -0.38, P = 0.008) (Figure 2B).
A positive correlation was observed between urine
HMGB1/Cr ratios and proteinuria (r = 0.57, P < 0.0001)
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Figure 1 High mobility group box 1 (HMGB1) concentrations in serum and urine from SLE patients with active lupus nephritis (LN),
patients without active LN but with a history of LN, patients without history of LN, and healthy controls (HC). (A) Serum HMGB1 levels.
(B) Urine HMGB1 levels. (C) Urine HMGB1 levels corrected for urine creatinine levels. Horizontal lines represent the median. (D) Representative
blots for urine HMGB1 measurement; lane 1: molecular weight marker, lanes 2, and 18: positive control, lanes 3, 5, 7, 9, 11, 13, and 15: urine
samples of SLE patients, lane 17: urine of HC.
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(Figure 2C). Next we assessed the relation between
serum HMGB1 and proteinuria in order to analyze
whether urinary HMGB1 passively results from protei-
nuria. In this group of patients, serum HMGB1 levels
were not correlated to proteinuria (Figure 3A). However,
urinary HMGB1 and serum HMGB1 levels were posi-
tively correlated (r = 0.28, P = 0.056) (Figure 3B).
Release of nuclear HMGB1 in the kidney
To assess the role of HMGB1 in renal inflammation or
damage we assessed the presence and localization of
HMGB1 in renal biopsies taken from patients with active
LN in comparison to control renal tissue. In control
renal tissue, HMGB1 was mainly present in the nuclei
with minor cytoplasmic staining in the tubuli (Figure 4C)
and in the glomeruli (Figure 4D). In biopsy sections from
patients with LN, HMGB1 was no longer confined to the
nuclei only, but was mainly expressed in the cytoplasm
and the extracellular space (Figure 4E and 4F). In these
patients, significant percentages of HMGB1 negative
nuclei (resulting from HMGB1 release) were present.
The percentage of HMGB1-negative nuclei was counted
and data are summarized in Table 2. Although the glo-
merular structures of patients with active LN showed
significant extracellular staining of HMGB1, only a few
HMGB1-negative nuclei were detected in glomeruli.
No correlation was found between the percentages of
HMGB1 negative nuclei in renal tissue and levels of
urinary HMGB1. We further assessed the association
between the percentage of HMGB1 negative nuclei in the
kidney, and histological findings such as activity index
(AI) and chronicity index (CI) and renal function para-
meters (eGFR, creatinine and proteinuria). No correlation
was found between histological scores and HMGB1 nega-
tive nuclei in the kidney (data not shown). Although no
correlation was found between HMGB1 negative nuclei
in the kidney and renal parameters (creatinine and pro-
teinuria), there was a trend toward a negative correlation
with estimated glomerular filtration rate (eGFR) (r =
-0.51, P = 0.05).



















































Figure 2 Correlation of urinary high mobility group box 1 (HMGB1)/creatinine (Cr) ratios in systemic lupus erythematosus (SLE)
patients with systemic lupus erythematosus disease activity index (SLEDAI), complement levels C3, and proteinuria. HMGB1/Cr ratios
correlate positively with SLEDAI scores (A), and proteinuria (C) and inversely with C3 (B).
Abdulahad et al. Arthritis Research & Therapy 2012, 14:R184
http://arthritis-research.com/content/14/4/R184








































Figure 3 Correlation of serum levels of high mobility group box 1 (HMGB1) with proteinuria and urinary HMGB1/creatinine (Cr) ratios.
(A) Serum HMGB1 levels are not significantly correlated to proteinuria. (B) Positive correlation between serum HMGB1 and urine levels of
HMGB1.
Figure 4 Expression of high mobility group box 1 (HMGB1) in renal tissue of active lupus nephritis (LN) patients and controls.
Representative immunohistochemical staining of HMGB1 in a renal biopsy from an active LN patient (E,F) and control renal tissue (C,D). Isotype
staining in control tissue (A,B). Renal tissue of the active LN patient shows a higher percentage of HMGB1-negative nuclei in tubular cells (E) and
strong cytoplasmic and extracellular staining for HMGB1 in tubuli and glomeruli (F). Biopsy taken from normal renal tissue shows expression of
HMGB1 mainly inside nuclei (C,D).
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Expression of HMGB1 receptors (TLR2, TLR4 and RAGE) in
the kidney of LN patients and controls
As expression and release of HMGB1 was increased in the
renal biopsies from LN patients, we further analyzed the
expression of HMGB1 receptors, that is, TLR2, TLR4 and
RAGE, in these biopsies as well as in control renal tissue.
Control renal tissue showed relatively weak expression of
TLR2, TLR4 and RAGE with 14% (12 to 16%) for TLR2,
14% (12 to 16%) for TLR4 and 0.2% (0.004 to 0.500%) for
RAGE. In contrast, strong expression of TLR2, TLR4 and
RAGE was observed in renal biopsies from patients with
active LN compared to control renal tissue, with 28.7 (24.7
to 50.0%), P < 0.008, for TLR2; 28.8% (20 to 40%), P <
0.008, for TLR and 29% (17 to 40%), P < 0.008, for RAGE.
Expression of TLR2, TLR4 and RAGE in active LN
patients was mainly cytoplasmic and localized in glomeruli
as wells as in tubular cells (Figure 5). Expression of various
receptors was not associated with the percentage of
HMGB1-negative nuclei in renal biopsies from patients
with active LN, SLEDAI and renal function parameters.
Discussion
In the present study we demonstrated for the first time
that HMGB1 levels are significantly increased in the
urine of SLE patients especially in those with active pro-
liferative LN. Moreover, urinary levels of HMGB1 were
correlated with disease activity scores, and reversely
with levels of complement C3.
LN is a serious manifestation in patients with SLE that
can progress to end-stage renal failure. Despite extensive
studies, the pathogenesis of LN has not been fully clarified.
Recently, the role of HMGB1 has been demonstrated in
autoimmunity and chronic inflammatory diseases, espe-
cially those with renal manifestations such as antineutro-
phil cytoplasmic antibody (ANCA)-associated vasculitis,
chronic kidney disease (CKD) and SLE [15,17,20-25].
Figure 5 Expression of high mobility group box 1 (HMGB1) receptors in a renal biopsy from a patient with active lupus nephritis (LN)
and in control renal tissue. Representative staining for RAGE, TLR2 and TLR4 in active LN (D,E,F) and control renal tissue (A,B,C), respectively.
Renal tissue of an active LN patient shows strong cytoplasmic/extracellular expression for HMGB1 receptors in tubular cells, interstitial infiltrates,
and glomeruli in comparison to control tissue.
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However, until now no study has been conducted to eval-
uate urinary levels of HMGB1 as a reflection of renal
inflammation. Thus, in the current study we investigated
urine levels of HMGB1, in comparison to serum levels,
in SLE patients with and without renal involvement. In
accordance with our previous study, serum levels of
HMGB1 were significantly increased in active LN patients
compared to patients without active renal disease and con-
trols [15]. Similarly, urinary levels of HMGB1 were
increased in patients with active LN. Of note, urinary
HMGB1 levels were also detectable, but at a lower level, in
patients without active LN, but not in HC. Detectable
amounts of HMGB1 in the urine of patients without active
LN might be explained in two ways. A possibly ongoing
low-grade renal inflammatory activity could contribute to
the release of HMGB1. Indeed, Zickert et al. showed that
extracellular expression of HMGB1 is detectable in renal
biopsies taken from quiescent SLE patients at follow up
[26]. Furthermore, some patients with SLE may have nega-
tive urine findings despite histological evidence of lupus
nephritis [27]. Second, increased levels of serum HMGB1
might lead to urinary excretion of HMGB1, particularly in
patients with a history of LN and slight persisting protei-
nuria. HMGB1 has been recognized as a new autoantigen
and as an important inflammatory mediator in SLE as
exemplified by increased serum levels and presence of
antibodies against this protein [15-17]. Both HMGB1 and
anti-HMGB1 antibodies have been shown to be associated
with SLE disease activity, decreased complement levels,
and proteinuria [15]. In our present study however, we did
not find a positive correlation of HMGB1 serum levels
with proteinuria. Now a large group of patients with newly
diagnosed active LN without induction therapy was
included in contrast to our previous study. This may
explain the discrepancy in findings between both studies.
Nevertheless, the absence of a correlation in the present
study is not fully explained.
Interestingly, in the current study urinary HMGB1
levels were correlated with SLEDAI, particularly in
patients with active LN. Furthermore, urinary levels of
HMGB1 were inversely correlated with complement
levels. We were not able to determine prospectively if
urine levels of HMGB1 can be used for monitoring renal
disease activity in patients with active LN. Nevertheless,
increased urine levels of HMGB1 might indicate that
HMGB1 is an important inflammatory mediator and that
urinary HMGB1 might be an additional biomarker for
assessment of renal disease activity in SLE. However,
more studies are needed to ascertain that urinary levels
of HMGB1 are a clinically useful marker.
The exact events leading to glomerular inflammation
and damage are still not known. Anti-dsDNA or anti-
nucleosome antibodies, present in immune complexes,
have been suggested as important players. It has been
shown that HMGB1 is an important component of these
circulating DNA-containing immune complexes [6].
HMGB1 is responsible for immune-inflammatory activity
and for binding of DNA-containing immune complexes,
containing anti-dsDNA and/or anti-HMGB1 antibodies,
to renal tissue, causing injury. However, the origin of
HMGB1, whether it is produced outside the kidney or
locally within the inflamed kidney, is still unresolved. In
the current study, the percentage of HMGB1-negative
nuclei, probably resulting from HMGB1 release, was
higher in renal tissue of patients with active LN com-
pared to control renal tissue, suggesting active release of
HMGB1 in pro-inflammatory processes within the kid-
ney. Our results are in line with the findings of Qing
et al. [6]. In their study, specific data on the characteris-
tics of their LN patients were not mentioned, and levels
of HMGB1 in serum were not detectable. Also, urinary
levels of HMGB1 were not measured. We were not able
to definitely identify the cells releasing HMGB1. Release
of HMGB1 could result from infiltrating cells as indi-
cated by immunohistochemical staining, but could also
result from either activation or cell death of constitutive
renal tissue. Also, we cannot exclude the possibility that
at least some of urinary HMGB1 might emerge from sys-
temic inflammation. This might explain the lack of corre-
lation between urinary HMGB1 and HMGB1 released
from nuclei in the kidney. Further support for the role of
HMGB1 in renal inflammation comes from the increased
expression of the HMGB1 receptors TLR2, TLR4 and
RAGE in the renal tissue of LN patients. To the best of
our knowledge, this is the first study describing expres-
sion of the functional receptors (TLR2, TLR4 and RAGE)
of HMGB1 in lupus nephritis. The low intrinsic expres-
sion of these receptors in control tissue suggests that
TLR2, TLR4, and RAGE are all part of the innate
immune system in the kidney. The intense and altered
expression of TLR2, TLR4, and RAGE in patients with
active LN, however, could reflect a role of these receptors
in the development and severity of lupus nephritis. In
combination, all these data indicate that HMGB1 might
be an important player in the pathogenesis of LN and,
possibly, a therapeutic target. Indeed, Mao et al. demon-
strated that targeting HMGB1 by monoclonal antibodies
in a murine adenovirus-accelerated SLE model inhibited
the development of proteinuria and proved protective
[28]. Clinical studies targeting HMGB1, however, have
not been performed.
The present study provides evidence that HMGB1
expression is increased not only in the sera but also in
the urine of active LN patients as well as at the site of
local renal inflammation. Urine levels of HMGB1 could
reflect both local and systemic inflammation. Urinary
biomarkers might be more relevant than serum biomar-
kers because they may directly reflect renal pathology.
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However, further studies are needed to evaluate the clini-
cal significance of measuring urinary HMGB1 and its
value as a biomarker in lupus patients with renal
involvement.
Conclusions
The present study demonstrated increase in urine
HMGB1 levels in SLE patients, in particular in those with
active LN. Increase in urine HMGB1 levels correlated to
SLE disease activity index (SLEDAI). Accordingly, renal
tissue of LN patients showed increase in nuclear HMGB1
release compared to control tissue. Furthermore, expres-
sion of TLR2, TLR4 and RAGE was increased in a renal
biopsy from active LN patients. Together, we suggest that
HMGB1 may play an important role in renal pathology in
SLE patients.
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